Nirsevimab has the potential to offer RSV protection for all infants, with a single dose showing 74.5 percent efficacy in the Melody Phase III trial.
List view / Grid view
Chronic lung disease
“We will work with health care professionals and patients to develop a form of rehabilitation that will be acceptable to all those involved."
Oral steroids should not be used for treating acute lower respiratory tract infection in adults who don't have asthma or other chronic lung disease...